FLGT
Fulgent Genetics, Inc.
+0.17 (+0.79%)21.80USD74.4K成交股數600M市值–本益比(近四季)1.9股價營收比+4.4%營收年增(近四季)2026-11-06下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 85.4M+16% | 71.1M-7% | 84.1M+17% | 81.8M+15% | 73.5M+14% | 76.2M-10% | 71.7M+6% | 71.0M+7% | 64.5M | 84.7M | 67.9M | 66.2M |
| 營業成本 | 59.7M | 49.6M | 48.6M | 47.4M | 45.1M | 44.4M | 45.0M | 44.5M | 42.4M | 44.8M | 47.3M | 47.4M |
| 毛利 | 25.7M-9% | 21.5M-33% | 35.5M+33% | 34.4M+30% | 28.3M+28% | 31.8M-20% | 26.8M+30% | 26.5M+41% | 22.1M | 39.8M | 20.6M | 18.8M |
| 毛利率 | 30.1% | 30.2% | 42.2% | 42.1% | 38.6% | 41.8% | 37.3% | 37.3% | 34.3% | 47.0% | 30.3% | 28.4% |
| 研發費用 | 14.6M | 14.2M | 13.9M | 13.5M | 12.4M | 12.1M | 11.8M | 13.5M | 11.4M | 10.0M | 9.7M | 9.8M |
| 銷售管理費用 | 27.2M | 27.7M | 23.3M | 26.4M | 25.3M | 24.3M | 21.0M | 21.3M | 21.5M | 17.5M | 18.0M | 21.8M |
| 營業利益 | −36.1M+82% | −34.6M+115% | −15.4M-10% | −19.7M+4% | −19.8M-9% | −16.1M-7640% | −17.1M-14% | −18.9M-24% | −21.8M | 214K | −19.8M | −24.8M |
| 營業利益率 | -42.2% | -48.7% | -18.3% | -24.1% | -26.9% | -21.2% | -23.8% | -26.6% | -33.8% | 0.3% | -29.2% | -37.5% |
| 稅後淨利 | −29.5M+156% | −24.8M+322% | −6.6M-55% | −19.0M+118% | −11.5M-14% | −5.9M-55% | −14.6M+30% | −8.7M-43% | −13.5M | −13.1M | −11.2M | −15.3M |
| 淨利率 | -34.6% | -34.9% | -7.9% | -23.2% | -15.7% | -7.7% | -20.4% | -12.3% | -20.9% | -15.5% | -16.5% | -23.2% |
| 稀釋 EPS | – | – | – | – | – | – | – | – | – | – | – | – |
| 稀釋股數 | 28.0M | 30.9M | 30.7M | 30.5M | 30.8M | 30.2M | 30.4M | 30.1M | 29.8M | 30.0M | 29.8M | 29.5M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 26.3M | 23.4M | 118M | 87.9M | 67.3M | 55.1M | 58.0M | 65.1M | 54.7M | 84.1M | 58.3M | 66.2M |
| 應收帳款 | 64.9M | 69.3M | 71.2M | 77.2M | 71.5M | 69.0M | 57.3M | 56.6M | 52.1M | 49.3M | 34.8M | 43.5M |
| 存貨 | 793K | 770K | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 1.1B | 1.2B | 1.2B | 1.2B | 1.2B | 1.2B | 1.2B | 1.2B | 1.2B | 1.4B | 1.4B | 1.4B |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 93.2M | 112M | 93.8M | 88.2M | 83.0M | 90.8M | 98.9M | 103M | 103M | 96.6M | 91.3M | 108M |
| 股東權益 | 1.0B | 1.0B | 1.1B | 1.1B | 1.1B | 1.1B | 1.1B | 1.1B | 1.1B | 1.3B | 1.3B | 1.3B |
| 負債比 | 8.6% | 9.7% | 7.7% | 7.4% | 6.9% | 7.4% | 8.0% | 8.4% | 8.4% | 7.1% | 6.7% | 7.8% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 7.1M | – | – | −4.4M-161% | – | – | – | 7.3M | – | – | −7.9M |
| 資本支出 | – | 5.2M | – | – | 4.7M | – | – | – | 4.1M | – | – | 2.0M |
| 自由現金流 | – | 1.9M | – | – | −9.1M-385% | – | – | – | 3.2M | – | – | −9.9M |
| 折舊攤銷 | – | 6.0M | – | – | 5.9M | 6.2M | 5.9M | 6.2M | 6.7M | 6.4M | 6.3M | 6.9M |
| 買回庫藏股 | – | 40.1M | – | – | 8.7M | – | – | – | 225K | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | 2.7% | – | – | -12.5% | – | – | – | 5.0% | – | – | -15.0% |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 323M
| Laboratory Services | 322M | 99.9% | +13.7% |
|---|---|---|---|
| Therapeutic Development | 447K | 0.1% | – |
地區2025 年度 · 323M
| 美國 | 297M | 91.9% | +14.4% |
|---|---|---|---|
| 其他國家 | 13.2M | 4.1% | +12.9% |
| 中國 | 12.9M | 4.0% | +2.1% |
| 美國以外 小計 | 26.1M | 8.1% | +7.3% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 323M | +13.8% | −60.5M | -18.8% | – | −124M |
| FY2024 | 283M | -2.0% | −42.7M | -15.1% | – | −19.3M |
| FY2023 | 289M | -53.3% | −168M | -58.0% | – | 4.8M |
| FY2022 | 619M | -37.6% | 143M | 23.2% | – | 235M |
| FY2021 | 993M | +135.4% | 507M | 51.1% | – | 515M |
| FY2020 | 422M | +1196.5% | 214M | 50.8% | – | 105M |
| FY2019 | 32.5M | +52.3% | −411K | -1.3% | – | 4.3M |
| FY2018 | 21.4M | – | −5.6M | -26.3% | – | −3.0M |